About Us

GeneCentric Company Overview

GeneCentric Therapeutics is applying proprietary technology to identify drug responder populations that enable the development of precision cancer drugs while improving patient outcomes.

Our initial approach applies our Cancer Subtype Platform (CSP®) to parse the complexity of tumor biology and generate genomic signatures. This approach yields high-resolution cancer subtypes with the potential to function as universal biomarkers for susceptibility to immune-based, targeted and other therapies.

In commercializing our technology through strategic collaborations with pharmaceutical and biotech companies, we are defining responder populations based on subtypes throughout the drug development cycle.

Leadership

Dr. Myla Lai-Goldman, MD

Founder & Chief Executive Officer

Dr. Hawazin Faruki, DrPH

Chief Scientific Officer

Walter M. Capone, MBA

Chief Business Officer

Clay Thorp

Chairman

Dr. Myla Lai-Goldman, MD

Founder & Chief Executive Officer

Ellen Lubman

Director

Dr. Arnold J. Levine, Phd

Director

Dr. Charles M. Pereou, PhD

Founder and Director

Dr. David Neil Hayes, MD MPH MS

Founder

Dr. Charles M. Pereou, PhD

Founder and Director

Dr. Myla Lai-Goldman, MD

Founder & Chief Executive Officer

Making News: Our Latest Progress, Partnerships and Impact

GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cance ...

LEARN MORE

GeneCentric Therapeutics CEO and Founder Dr. Myla-Lai Goldman to be featured on ”Radio In Vivo: Yo ...

LEARN MORE

Differences in BRCAness/PARP Inhibitor Response Signatures and Homologous Recombination Gene Express ...

LEARN MORE